Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs & Aging
Published in: Drugs & Aging 11/2002

01-11-2002 | Review Article

Role of Hormones in the Pathogenesis and Management of Sarcopenia

Authors: Dr Hosam K. Kamel, Diana Maas, Edmund H. Duthie Jr

Published in: Drugs & Aging | Issue 11/2002

Login to get access

Abstract

There is growing evidence to indicate that age-related declines in growth hormone (GH), insulin-like growth factor (IGF)-1, and androgen and estrogen production play a role in the pathogenesis of sarcopenia (an age-related decline in muscle mass and quality). Although GH supplementation has been reported to increase lean body mass in elderly individuals, the high incidence of adverse effects combined with a very high cost has limited the applicability of this form of therapy. The assessment of an alternative approach to enhance the GH/IGF-1 axis in the elderly by using GH-releasing hormone and other secretagogues is currently under way and is showing some promise. Testosterone replacement therapy may increase muscle mass and strength and decrease body fat in hypogonadal elderly men. Long-term randomised, controlled trials are needed, however, to better define the risk-benefit ratio of this form of therapy before it can be recommended. Available data are currently insufficient to decide what role estrogen replacement therapy may play in the management of sarcopenia.
Therefore, although the evidence linking age-related hormonal changes to the development of sarcopenia is rapidly growing, it is still too early to determine the clinical utility of hormonal supplementation in the management of sarcopenia.
Literature
1.
Baumgartner RN, Stauber PM, McHugh D, et al. Cross-sectional age differences in body composition in persons 60+ years of age. J Gerontol A Biol Sci Med Sci 1995; 50: M307–16PubMedCrossRef
2.
Rosenberg IH. Sarcopenia: origins and clinical relevance. J Nutr 1997; 127: 990S–1SPubMed
3.
4.
Roubenoff R. The pathophysiology of wasting in the elderly. J Nutr 1999; 129: 256S–9SPubMed
5.
Alexander NB, Schultz A, Warwick DN. Rising from a chair: effects of age and functional ability on performance biomechanics. J Gerontol 1991; 46: M91–8PubMedCrossRef
6.
Hubert HB, Bloch DA, Fries JF. Risk factors for physical disability in an aging cohort: the NHANES 1 epidemiologic follow-up study. J Rheumatol 1993; 20: 480–8PubMed
7.
Guralink JM, Simonsick EM, Ferrucci L, et al. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol 1994; 49: M85–94CrossRef
8.
Kritz-Silverstein D, Barrett-Conner E. Grip strength and bone mineral density in older women. J Bone Miner Res 1994; 9: 45–52PubMedCrossRef
9.
Toner MM, Sawka MN, Foley ME, et al. Effects of body mass and morphology on thermal responses in water. J Appl Physiol 1986; 60: 521–5PubMedCrossRef
10.
Kohert WM, Kirwan JP, Staten MA, et al. Insulin resistance in aging is related to abdominal obesity. Diabetes 1993; 42: 273–81CrossRef
11.
Dutta C, Hadley E. The significance of sarcopenia in old age. J Gerontol 1995; 50(A): 1–4
12.
Baumgartner RN, Koehler KM, Gallagher D, et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol 1998; 147: 755–63PubMedCrossRef
13.
Melton J, Khosla S, Crowson C, et al. Epidemiology of sarcopenia. J Am Geriatr Soc 2000; 48: 625–30PubMed
14.
Navarro A, Lopez-Cepero JM, Sanchez del Pino MJ. Skeletal muscle and aging. Front Biosci 2001; 6: d26–44PubMedCrossRef
15.
Allen TH, Anderson EC, Langham WH. Total body potassium and gross body composition in relationship to age. J Gerontol 1960; 15: 348–57PubMedCrossRef
16.
Tzankoff SP, Norris AH. Effect of muscle mass decrease on age-related BMR changes. J Appl Physiol 1977; 43: 1001–6PubMed
17.
Young A, Stokes M, Crowe M. Size and strength of the quadriceps muscles of old and young men. Clin Physiol 1985; 5: 145–54PubMedCrossRef
18.
Young A, Stokes M, Crowe M. Size and strength of the quadriceps muscles of old and young women. Eur J Clin Invest 1984; 14: 282–7PubMedCrossRef
19.
Imamura K, Ashida H, Ishikawa T, et al. Human major psoas muscle and sacrospinalis muscle in relation to age: a study by computed tomography. J Gerontol 1983; 38: 678–81PubMedCrossRef
20.
Kligaard H, Mantoni M, Schianffino S, et al. Function, morphology and protein expression of aging skeletal muscle: a cross-sectional study of elderly men with different training backgrounds. Acta Physiol Scand 1990; 140: 119–39CrossRef
21.
Overend TJ, Cunningham DA, Paterson DH, et al. Thigh composition in young and elderly men determined by computed tomography. Clin Physiol 1992; 12: 629–40PubMedCrossRef
22.
Rice CL, Cunningham DA, Paterson DH, et al. Arm and leg composition determined by computed tomography in young and elderly men. Clin Physiol 1989; 9: 207–20PubMedCrossRef
23.
Tomonaga M. Histochemical and ultrastructural changes in senile human skeletal muscle. J Am Geriatr Soc 1977; 25: 125–31PubMed
24.
Jennekens FG, Tolinson BE, Walton J. Histochemical aspects of five limb muscles in old age: an autopsy study. J Neurol Sci 1971; 14: 259–76PubMedCrossRef
25.
Balagopal P, Rooyackers OE, Adey DB, et al. Effects of aging on in vivo synthesis of skeletal muscle myosin heavy-chain and sarcoplasmic protein in humans. Am J Physiol 1997; 273: E790–800PubMed
26.
Lexell J, Henriksson-Larsen K, Winblad B, et al. Distribution of different fiber types in human skeletal muscle: effects of aging studied in whole muscle-cross sections. J Appl Physiol 1985; 59: 1228–36PubMed
27.
Jakobson F, Borg K, Edstrom L. Fiber-type composition, structure and cytoskeletal protein location of fibers in anterior tibial muscle: comparison between young adults and physically active aged humans. Acta Neuropathol 1990; 80: 459–69CrossRef
28.
Doherty TJ, Brown WF. The estimated number and relative size of thenar motor units as selected by multiple point stimulation in young and older adults. Muscle Nerve 1993; 74: 868–74
29.
Wanagat J, Cao Z, Pathare P, et al. Mitochondrial DNA deletion mutations co localize with segmental electron transport system abnormalities, muscle fiber atrophy, fiber splitting, and oxidative damage in sarcopenia. FASEB J 2001; 15(2): 322–32PubMedCrossRef
30.
Weindruch R. Interventions based on the possibility that oxidative stress contributes to sarcopenia. J Gerontol A Biol Sci Med Sci 1995; 50: 157–61PubMed
31.
Doherty TJ, Vandervoort AA, Taylor AW, et al. Effects of aging on the motor unit: a brief review. Can J Appl Physiol 1992; 18: 331–58CrossRef
32.
Tomlinson BE, Irving D. The numbers of limb motor neurons in the human lumbosacral cord throughout life. J Neurol Sci 1977; 34: 213–9PubMedCrossRef
33.
Welle S, Thornton T, Jozefowicz R, et al. Myofibrillar protein synthesis in young and old men. Am J Physiol 1993; 26: E693–8
34.
Balagopal P, Rooyackers OE, Adey DB, et al. Effects of aging on in vivo synthesis of skeletal muscle myosine heavy-chain and sarcoplasmic protein in humans. Am J Physiol 1997; 273: E790–800PubMed
35.
Clement FJ. Longitudinal and cross-sectional assessments of age changes in physical strength as related to sex, social class, and mental ability. J Gerontol 1974; 29: 423–9PubMedCrossRef
36.
Larsson L, Grimby G, Karlsson J. Muscle strength and speed of movement in relation to age and muscle morphology. J Appl Physiol 1979; 46: 451–6PubMed
37.
Murray MP, Gardner GM, Mollinger LA, et al. Strength of isometric and isokinetic contractions. Phys Ther 1980; 60: 412–9PubMed
38.
Johnson T. Age-related differences in isometric and dynamic strength and endurance. Phys Ther 1982; 62: 985–9PubMed
39.
Viitasalo JT, Era P, Leskinen AL, et al. Muscular strength profiles and anthopometry in random samples of men aged 31–35, 5155, and 71–75 years. Ergonomics 1985; 28: 1563–74CrossRef
40.
Frontera WR, Hughes VA, Lutz KJ, et al. A cross-sectional study of muscle strength and mass in 45–78-year-old men and women. J Appl Physiol 1991; 71: 644–50PubMed
41.
Era P, Lyyra AL, Viitasalo JT, et al. Determinants of isometric muscle strength in men of different ages. Eur J Appl Physiol 1992; 64: 84–91CrossRef
42.
Asmussen E, Heeboll-Nielsen K. Isometric muscle strength in relation to age in men and women. Ergonomics 1962; 5: 167–9CrossRef
43.
Harries UJ, Bassey EJ. Torque-velocity relationships for the knee extensors in women in their 3rd and 7th decades. Eur J Appl Physiol 1990; 60: 187–90CrossRef
44.
Maurray MP, Duthie Jr EH, Gambert SR, et al. Age-related differences in knee muscle strength in nominal women. J Gerontol 1985; 40: 275–80CrossRef
45.
Young A, Stokes M, Crowe M. Size and strength of the quadriceps muscles of old and young women. Eur J Clin Invest 1984; 14: 282–7PubMedCrossRef
46.
Stalberg E, Borges O, Ericsson M, et al. The quadriceps femoris muscle in 20–70-year-old subjects: relationships between knee extension torque electrophysiological parameters, and muscle fiber characteristics. Muscle Nerve 1989; 12: 382–9PubMedCrossRef
47.
Aniansson A, Sperling L, Rundgren A, et al. Muscle function in 75-year-old men and women: a longitudinal study. Scand J Rehabil Med Suppl 1983; 9: 92–102PubMed
48.
Aniansson A, Hedberg M, Henning GB, et al. Muscle morphology, enzymatic activity, and muscle strength in elderly men: a follow-up study. Muscle Nerve 1986; 9: 585–91PubMedCrossRef
49.
Aniansson A, Grimby G, Hedberg N. Compensatory muscle fiber hypertrophy in elderly men. J Appl Physiol 1992; 73: 812–6PubMed
50.
Bassey EJ, Harries UJ. Normal values for hand grip strength in 920 men and women aged over 65 years, and longitudinal changes over 4 years in 620 survivors. Clin Sci 1993; 84: 331–7PubMed
51.
Tanaka H, Seals DR. Age and gender interactions in physiological functional capacity: insight form swimming performance. J Appl Physiol 1997; 82(3): 846–51PubMed
52.
Dempsey JA, Seals DR. Aging, exercise and cardiopulmonary function. In: Lamb DR, Gisolfi CV, Nadel E, editors. Perspectives in exercise science and sports medicine: exercise in older adults. Carmel (IN): Cooper, 1995: 237–304
53.
Joyner MJ. Physiological limiting factors and distance running: influence of gender and age on record performances. In: Holloszy JO, editor. Exercise and sport science reviews. Baltimore (MD): Williams & Wilkins, 1993: 103–33
54.
Conley KE, Kemper WF, Crowther GJ. Limits to sustainable muscle performance: interaction between glycolysis and oxidative phosphorylation. J Exp Biol 2001; 204 (Pt 18): 3189–94PubMed
55.
Conely KE, Esselman PC, Jubrias SA, et al. Ageing, muscle properties and maximal O(2) uptake rate in humans. J Physiol 2000; 526 Pt 1: 211–7CrossRef
56.
Fiatarone MA, O’Neill EF, Ryan ND, et al. Exercise training and nutritional supplementation for physical frailty in very elderly people. N Engl J Med 1994; 330: 1769–75PubMedCrossRef
57.
Bendall MJ, Bassey EJ, Pearson MB. Factors affecting walking speed of elderly people. Age Ageing 1989; 18: 327–32PubMedCrossRef
58.
Vellas B, Baumgartner RN, Wayne SJ, et al. Relationship between malnutrition and falls in the elderly. Nutrition 1992; 8: 105–8PubMed
59.
Roubenoff R, Hughes VA. Sarcopenia: current concepts. J Gerontol 2000; 55A(12): M716–24
60.
Rudman D. Growth hormone, body composition, and aging. J Am Geriatr Soc 1985; 33: 800–1PubMed
61.
Kelijman M. Age-related alterations of growth hormone/insulin-like-growth-factor I axis. J Am Geriatr Soc 1991; 39: 295–307PubMed
62.
Jorgensen JO, Pedersen SA, Thuesen L, et al. Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet 1989; I: 1221–5CrossRef
63.
Binnerts A, Deurenberg P, Swat GR, et al. Body composition in growth hormone-deficient adults. Am J Clin Nutr 1992; 55: 918–23PubMed
64.
Debore H, Block GJ, Voerman HJ, et al. Body composition in adult growth hormone-deficient men, assessed by anthropometry and bioimpedance. J Clin Endocrinol Metab 1986; 75: 833–7
65.
Rudman D, Feller AG, Nagraj HS, et al. Effects of human growth hormone in men over 60 years old. N Engl J Med 1990; 323: 1–6PubMedCrossRef
66.
Cohen L, Feller AG, Draper MW, et al. Carpal tunnel syndrome and gynaecomastia during growth hormone treatment of elderly men with low circulating IGF-1 concentrations. Clin Endocrinol 1993; 39: 417–25CrossRef
67.
Papadakis MA, Grady B, Black D, et al. Growth hormone replacement in healthy older men improves body composition but not functional ability. Ann Intern Med 1996; 124: 708–16PubMed
68.
Kaiser FE, Silver AJ, Morley JE. The effect of recombinant human growth hormone on malnourished older individuals. J Am Geriatr Soc 1991; 39: 235–40PubMed
69.
Chu LW, Lam KS, Tam SC, et al. A randomized controlled trial of low-dose recombinant human growth hormone in the treatment of malnourished elderly medical patients. J Clin Endocrinol Metab 2001; 86(5): 1913–20PubMedCrossRef
70.
Takala J, Ruokonen E, Webster NR, et al. Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med 1999; 341: 785–92PubMedCrossRef
71.
Bengtsson B, Eden S, Lonn L, et al. Treatment of adults with growth hormone deficiency with recombinant human GH. J Clin Endocrinol Metab 1993; 76(2): 309–31PubMedCrossRef
72.
Lissett CA, Shalet SM. Effects of growth hormone on bone and muscle. Growth Horm IGF Res 2000; 10 Suppl. B: S95–101PubMedCrossRef
73.
Iovino M, Monteleone P, Steardo L. Repetitive growth hormone-releasing hormone administration restores the attenuated growth hormone (GH) response to GH-releasing hormone testing in normal aging. J Clin Endocrinol Metab 1989; 69: 910–3PubMedCrossRef
74.
Corpas E, Harman SM, Pineyro MA, et al. Growth hormone (GH)-releasing hormone-(1–29) twice daily reverses the decreased GH and insulin like growth factor-1 levels in old men. J Clin Endocrinol Metab 1992; 75: 530–5PubMedCrossRef
75.
Chapman IM, Bach MA, Van Cauter E, et al. Stimulation of the growth hormone (GH)-insulin-like growth facto I axis by daily oral administration of a GH secretagogue (MK-677) in healthy elderly subjects. J Clin Endocrinol Metab 1996; 81(12): 4249–57PubMedCrossRef
76.
77.
Juul A, Bang P, Hertel NT, et al. Serum insulin-like growth factor-1 in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. J Clin Endocrinol Metab 1994; 78(3): 744–52PubMedCrossRef
78.
Hammerman MR. Insulin-like growth factors and aging. Endocrinol Metab Clin North Am 1987; 16(4): 995–1011PubMed
79.
80.
Corpas E, Harman SM, Blackman MR. Human growth hormone and human aging. Endocr Rev 1993; 14(1): 20–39PubMed
81.
Thissen J, Keteslegers JM, Underwood LE. Nutritional regulation of the insulin-like growth factors. Endocr Rev 1994; 15: 80–101PubMed
82.
Johnson TR, Blossey BK, Denko CW, et al. Expression of insulin-like growth factor-1 in cultural rat hepatocytes: effects of insulin and growth hormone. Mol Endocrinol 1989; 3: 580–7PubMedCrossRef
83.
Rutanen EM, Karkkainen T, Stenman UH, et al. Aging is associated with decreased suppression of insulin-like growth factor binding proteins and insulin sensitivity. J Clin Endocrinol Metab 1997; 82: 2177–81CrossRef
84.
Benbassat CA, Maki KC, Unterman TG. Circulating levels of insulin-like growth factor (IGF) binding protein-1 and -3 in aging men: relationships to insulin, glucose, IGF, and dehydroepiandrosterone sulfate levels and anthropometric measures. J Clin Endocrinol Metab 1997; 82(5): 1484–91PubMedCrossRef
85.
Veldhuis JD, Bidlingmaier S, Anderson SM, et al. Lowering total plasma insulin-like growth factor 1 concentrations by way of a novel, potent, and selective growth hormone (GH) receptor antagonist, pegvisomant (B2036-Peg), augments the amplitude of GH secretary bursts and elevates basal/non-pulsatile GH release in healthy women and men. J Clin Endocrinol Metab 2001; 86(7): 3304–10PubMedCrossRef
86.
Quinn LS, Haugk KL. Over expression of the type-1 insulin-like growth factor receptor increases ligand-dependent proliferation and differentiation in bovine skeletal myogenic cultures. J Cell Physiol 1996; 168(1): 34–41PubMedCrossRef
87.
Schwartz RS. Trophic factor supplementation: effect on the age-associated changes in body composition. J Gerontol Series A 1995; 50A: 151–6CrossRef
88.
Baumgartner R, Waters D, Gallgher D, et al. Predictors of skeletal muscle mass in elderly men and women. Mech Ageing Dev 1999; 107: 123–36PubMedCrossRef
89.
Perry HM, Miller DK, Patrick P, et al. Testosterone and leptin in older African-American men: relationship to age, strength, function, and season. Metabolism 2000; 49(8): 1085–91PubMedCrossRef
90.
Ashton WS, Degnan BM, Daniel A, et al. Testosterone increases insulin-like growth factor-1 and insulin-like growth factor-binding protein. Ann Clin Lab Sci 1995; 24: 381–8
91.
Urban RJ, Bodenburg YH, Gilkison C, et al. Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. Am J Physiol 1995; 269 (5 Pt 1): E820–6PubMed
92.
Morley JE, Perry III M, Kaiser FE, et al. Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study. J Am Geriatr Soc 1993; 41: 149–52PubMed
93.
Gentili A, Mulligan T, Godschalk M, et al. Unequal impact of short-term testosterone repletion on the somatotrophic axis of young and older men. J Clin Endocrinol Metab 2002; 87(2): 825–34PubMedCrossRef
94.
Gray A, Feldman HA, Mckinlay J, et al. Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab 1991; 73: 1016–25PubMedCrossRef
95.
Morley JE, Kaiser FE, Perry HM, et al. Longitudinal changes in testosterone, luteinizing hormone and follicle stimulating hormone in healthy older males. Metabolism 1997; 46: 410–4PubMedCrossRef
96.
Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrin Metab 1992; 75: 1092–8CrossRef
97.
Korenman SG, Morley JE, Mooradian AD, et al. Secondary hypogonadism in older men: its relationship to impotence. J Clin Endocrinol Metab 1990; 71: 963–9PubMedCrossRef
98.
Sih R, Morley JE, Kaiser FE, et al. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab 1997; 82(6): 1661–7PubMedCrossRef
99.
Snyder PJ, Peachey H, Hannoush P, et al. Effects of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab 1999; 84(8): 2647–53PubMedCrossRef
100.
Wang C, Swedloff RS, Iranmanesh A, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. Testosterone Gel Study Group. J Clin Endocrinol Metab 2000; 85(8): 2839–53PubMedCrossRef
101.
Brodsky IG, Balagopal P, Nair KS. Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men: a clinical research center study. J Clin Endocrinol Metab 1996; 81(10): 3469–75PubMedCrossRef
102.
Katznelson L, Finkelstein JS, Scheoenfeld DA, et al. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab 1996; 81(12): 4358–65PubMedCrossRef
103.
Bakhshi V, Elliot M, Gentili M, et al. Testosterone improves rehabilitation outcomes in ill older men. J Am Geriatr Soc 2001; 48(5): 550–3
104.
Ly LP, Jimernes M, Zhuang TN, et al. A double-blind, placebo-controlled, randomized clinical trial of transdermal dihydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiency. J Clin Endocrinol Metab 2001; 86(9): 4078–88PubMedCrossRef
105.
Morley JE, Kaiser FE, Raum WJ, et al. Potentially predictive and manipulable blood serum correlates of aging in the healthy human male: progressive decrease in bioavailable testosterone, and dehydroepiandrosterone sulfate. Proc Natl Acad Sci U S A 1997; 94: 7537–42PubMedCrossRef
106.
Abbasi A, Duthie EH, Sheldahl L, et al. Association of dehydroepiandrosterone sulfate, body composition, and physical fitness in independent community-dwelling older men and women. J Am Geriatr Soc 1998; 46: 263–73PubMed
107.
Morales AJ, Haubrich RH, Hwang JY, et al. The effect of six months treatment with a 100mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women. Clin Endocrinol 1998; 49: 421–32CrossRef
108.
Baulieu E, Thomas G, Legarain S, et al. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution ofthe DHEAge study to a sociomedical issue. Proc Natl Acad Sci U S A 2000; 97(8): 4279–84PubMedCrossRef
109.
Flynn MA, Weaver-Osterholtz D, Sharpe-Timms KL, et al. Dehydroepiandrosterone replacement in aging humans. J Clin Endocrinol Metab 1999; 84: 1527–33PubMedCrossRef
110.
Poehlman ET, Toth MJ, Gardner AW. Changes in energy balance and body composition at menopause: a controlled longitudinal study. Ann Intern Med 1995; 123(9): 673–5PubMed
111.
Grinspoon S, Corcoran C, Miller K, et al. Body composition and endocrine function in women with acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1997; 82: 1332–7PubMedCrossRef
112.
Pottratz ST, Bellido T, Mocharla H, et al. 17 alpha estradiol inhibits expression of human interleukin-6 promoter-reporter constructs by a receptor-dependent mechanism. J Clin Invest 1994; 93: 944–50PubMedCrossRef
113.
Ralston SH. Analysis of gene expression in human bone biopsies by polymerase chain reaction: evidence for enhanced cytokine expression in postmenopausal osteoporosis. J Bone Miner Res 1994; 9: 883–90PubMedCrossRef
114.
Veldhuis JD, Evans WS, Bowers CY, et al. Interactive regulation of postmenopausal growth hormone insulin-like growth factor axis by estrogen and growth hormone-releasing peptide-2. Endocrine 2001; 14(1): 45–62PubMedCrossRef
115.
Haarbo J, Marslew U, Gotfrdsen A, et al. Postmenopausal hormone replacement therapy prevents central distribution of body fat after menopause. Metabolism 1991; 40: 1323–6PubMedCrossRef
116.
Gower BA, Nyman L. Association among oral estrogen use, free testosterone concentrations, and lean body mass among postmenopausal women. J Clin Endocrinol Metab 2000; 85: 4476–80PubMedCrossRef
117.
Sorensen MB, Rosenfalck AM, Hojgaard L, et al. Obesity and sarcopenia after menopause are reversed by sex hormone replacement therapy. Obes Res 2001; 9(10): 622–6PubMedCrossRef
118.
Dionne JI, Kinaman KA, Poehlman ET. Sarcopenia and muscle function during menopause and hormone-replacement therapy. J Nutr Health Aging 2000; 4(3): 156–61PubMed
Metadata
Title
Role of Hormones in the Pathogenesis and Management of Sarcopenia
Authors
Dr Hosam K. Kamel
Diana Maas
Edmund H. Duthie Jr
Publication date
01-11-2002
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 11/2002
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.2165/00002512-200219110-00004

Other articles of this Issue 11/2002

Drugs & Aging 11/2002 Go to the issue

Leading Article

Hormone Replacement Therapy

Therapy In Practice

Atrial Fibrillation in the Elderly

Original Research Article

Potential Interactions between Herbal Medicines and Conventional Drug Therapies Used by Older Adults Attending a Memory Clinic

Therapy In Practice

Practical Management of Psoriasis in the Elderly
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits